Petter Brandal
YOU?
Author Swipe
View article: IMG-82. Positron emission tomography (PET) use among European Organisation for Research and Treatment of Cancer – Brain Tumour Group (EORTC-BTG) sites – a cross-sectional survey
IMG-82. Positron emission tomography (PET) use among European Organisation for Research and Treatment of Cancer – Brain Tumour Group (EORTC-BTG) sites – a cross-sectional survey Open
BACKGROUND Positron emission tomography (PET) is increasingly used in patients with brain tumors, yet its adoption varies across institutions. METHODS To assess the current landscape, a cross-sectional survey was conducted among European O…
View article: P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES
P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES Open
BACKGROUND Data on the use of positron emission tomography (PET) among neuro-oncology centers in Europe are scarce. MATERIAL AND METHODS From 06/2024 to 08/2024, a cross-sectional survey among European Organization for Research and Treatme…
View article: Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry
Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry Open
View article: A scoping review of proton radiation therapy and mutant-isocitrate dehydrogenase-inhibitors in IDH mutated lower-grade gliomas: pushing beyond surrogate end-points
A scoping review of proton radiation therapy and mutant-isocitrate dehydrogenase-inhibitors in IDH mutated lower-grade gliomas: pushing beyond surrogate end-points Open
Background Proton radiation therapy (PRT) and mutant isocitrate dehydrogenase inhibitors (mIDH-inhibitors) are emerging therapies for mIDH lower grade gliomas (LGGs). Despite their substantial theoretical benefits, comparisons with current…
View article: Prognostic value of 1D, 2D and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: radiological <i>post-hoc</i> analysis of the EORTC-BTG-1320 trial
Prognostic value of 1D, 2D and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: radiological <i>post-hoc</i> analysis of the EORTC-BTG-1320 trial Open
Background Although differential prognostic value of 1D, 2D and volumetric meningioma size assessment has been reported, RANO meningioma criteria rely on bidimensional measurements. Methods In this post-hoc analysis of the EORTC-BTG 1320 t…
View article: Protons or Photons in Pituitary Neuroendocrine Tumors—That Is Not the Question
Protons or Photons in Pituitary Neuroendocrine Tumors—That Is Not the Question Open
Proton techniques spared OARs better than VMAT; however, absolute dose sparing was relatively small, and the clinical value remains uncertain. Nonetheless, the dose reduction, especially for the hippocampi and integral dose, is probably cl…
View article: Availability and use of PET in patients with brain tumours – a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey
Availability and use of PET in patients with brain tumours – a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey Open
View article: Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3
Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3 Open
Background Radiation-induced changes following proton beam therapy in isocitrate dehydrogenase ( IDH )-mutated diffuse central nervous system (CNS) World Health Organization (WHO) grade 2 and 3 gliomas are not well characterized. We presen…
View article: Treatment-Aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction
Treatment-Aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction Open
Diffuse gliomas are malignant brain tumors that grow widespread through the brain. The complex interactions between neoplastic cells and normal tissue, as well as the treatment-induced changes often encountered, make glioma tumor growth mo…
View article: Spatial-Temporal Recurrence Patterns of Grade 4 Glioma Using Deep Learning Integrated mpMRI and Molecular Pathology:&nbsp;A Multi-Centre Longitudinal Study
Spatial-Temporal Recurrence Patterns of Grade 4 Glioma Using Deep Learning Integrated mpMRI and Molecular Pathology: A Multi-Centre Longitudinal Study Open
View article: OPTIMIZING RADIOTHERAPY FOR PITUITARY ADENOMAS - A TREATMENT PLANNING STUDY
OPTIMIZING RADIOTHERAPY FOR PITUITARY ADENOMAS - A TREATMENT PLANNING STUDY Open
View article: Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing
Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing Open
Aims The methylation status of the O6‐methylguanine‐DNA methyltransferase ( MGMT ) promoter region is essential in evaluating the prognosis and predicting the drug response in patients with glioblastoma. In this study, we evaluated the uti…
View article: The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients
The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients Open
View article: CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas
CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas Open
View article: Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study
Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study Open
Background: Surveillance of incidence and survival of central nervous system tumors is essential to monitor disease burden and epidemiological changes, and to allocate health care resources. Here, we describe glioma incidence and survival …
View article: Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study
Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study Open
Background Evaluation of molecular markers (IDH, pTERT, 1p/19q codeletion, and MGMT) in adult diffuse gliomas is crucial for accurate diagnosis and optimal treatment planning. Dynamic Susceptibility Contrast (DSC) and Arterial Spin Labelin…
View article: 500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study
500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study Open
View article: Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study
Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study Open
Background Differentiating post-radiation MRI changes from progressive disease (PD) in glioblastoma (GBM) patients represents a major challenge. The clinical problem is two-sided; avoid termination of effective therapy in case of pseudopro…
View article: Treatment-aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction
Treatment-aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction Open
Diffuse gliomas are malignant brain tumors that grow widespread through the brain. The complex interactions between neoplastic cells and normal tissue, as well as the treatment-induced changes often encountered, make glioma tumor growth mo…
View article: P11.75.B PSEUDOPROGRESSION IN A REAL-WORLD GLIOBLASTOMA COHORT: INCIDENCE, MANAGEMENT, PROGNOSTIC IMPACT, AND ASSOCIATED FACTORS
P11.75.B PSEUDOPROGRESSION IN A REAL-WORLD GLIOBLASTOMA COHORT: INCIDENCE, MANAGEMENT, PROGNOSTIC IMPACT, AND ASSOCIATED FACTORS Open
BACKGROUND Radiotherapy remains a cornerstone in glioblastoma (GBM) management. A continued and unmet need in neuro-oncology is efficient non-invasive methods to differentiate post-radiation magnetic resonance imaging (MRI) changes from pr…
View article: P03.14.A DUMMY RUN QUALITY ASSURANCE STUDY IN THE ONGOING PHASE 3 RANDOMIZED PRO-GLIO TRIAL
P03.14.A DUMMY RUN QUALITY ASSURANCE STUDY IN THE ONGOING PHASE 3 RANDOMIZED PRO-GLIO TRIAL Open
BACKGROUND PRO-GLIO is an ongoing multicenter phase 3 randomized controlled trial in Norway and Sweden. In this trial, 224 adult patients with isocitrate dehydrogenase (IDH) -mutated diffuse gliomas grade 2-3, astrocytomas and oligodendrog…
View article: The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study
The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study Open
Background New treatment modalities have not been widely adopted for patients with glioblastoma (GBM) after the addition of temozolomide to radiotherapy. We hypothesize that increased extent of resection (EOR) has resulted in improved surv…
View article: Supplementary Table S4 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Supplementary Table S4 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Supplementary Table S4
View article: Supplementary Table S4 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Supplementary Table S4 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Supplementary Table S4
View article: Supplementary Table S6 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Supplementary Table S6 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Supplementary Table S6
View article: Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of ag…
View article: Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Supplementary Figures and Legends
View article: Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Supplementary Table S3
View article: Supplementary Table S2 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Supplementary Table S2 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Supplementary Table S2
View article: Supplementary Table S5 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Supplementary Table S5 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes Open
Supplementary Table S5